人CCR5基因真核表达质粒的构建及其鉴定-东南大学学报医学版

人CCR5基因真核表达质粒的构建及其鉴定

单位：南京大学医学院公共健康医学中心,江苏南京 210093

分类号：R394.3

出版年·卷·期（页码）：2012·31·第一期（40-43）

摘要：

目的:构建人CCR5基因的真核表达质粒并对其进行功能鉴定。方法:PCR扩增人CCR5基因,将其克隆入真核表达载体pcDNA3.1内,构建含人CCR5基因的真核表达质粒pcDNA3.1-CCR5。使用RT-PCR、流式细胞术和HIV假病毒感染实验的方法,鉴定CCR5在真核细胞中的表达和功能。结果:克隆的人CCR5基因与GenBank中已登记的基因序列100%同源。瞬时转染真核细胞后,RT-PCR在预期的位置检测出目的条带,流式细胞术检测到约25.6%的细胞表达CCR5蛋白,且该蛋白能介导HIV假病毒的感染。结论:成功构建了含人CCR5基因的真核表达质粒。

Objective: To construct and characterize a eukaryotic system for expressing human CCR5 gene. Methods: Human CCR5 gene was amplified by PCR, and subcloned into pcDNA3.1 vector to construct a recombinant plasmid pcDNA3.1-CCR5. The expression of human CCR5 gene in eukaryotic cells was verified by RT-PCR and flow cytometry. HIV-1 env pseudotyped virus infection assay was used to detect the function of CCR5 gene in eukaryotic cells. Results: The sequence of inserted CCR5 gene fragment was 100% homology compared to human CCR5 gene registered in GenBank. After transfection of eukaryotic cells with pcDNA3.1-CCR5, the target band was identified by RT-PCR and about 25.6% of the CCR5 protein was detected by flow cytometry. Furthermore, the protein could mediate HIV pseudotype virus infection. Conclusion: A functional eukaryotic expression plasmid pcDNA3.1-CCR5 has been established successfully.

参考文献：

[1] GILLIAM B L,RIEDEL D J,REDFIELD R R.Clinical use of CCR5 inhibitors in HIV and beyond[J].J Transl Med,2011,9(Suppl 1 S9):1-14.
[2] 程林,卢春,陈秀英,等.人类疱疹病毒8型病毒干扰素调节因子编码基因的克隆及在真核细胞中的表达[J]. 南京医科大学学报:自然科学版,2006,26(12):1145-1149.
[3] 郭莉婷,陈颖,程月新,等.胃癌组织中B7-H4的表达及其临床意义[J].东南大学学报:医学版,2010,29(3):306-311.
[4] ALLERS K,HUTTER G,HOFMANN J,et al.Evidence for the cure of HIV infection by CCR5 Δ32/Δ32 stem cell transplantation[J].Blood,2011,117(10):2791-2799.
[5] LI L,SUN T,YANG K,et al.Monoclonal CCR5 antibody for treatment of people with HIV infection[J].Cochrane Database Syst Rev,2010,8(12):1-9.
[6] SCHANZER J,JEKLE A,NEZU J,et al.Development of tetravalent,bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains[J].Antimicrob Agents Chemother,2011,55(5):2369-2378.
[7] DA L T,WU Y D.Theoretical studies on the interactions and interferences of HIV-1 glycoprotein gp120 and its coreceptor CCR5[J].J Chem Inf Model,2011,51(2):359-369.
[8] PASTORI C,WEISER B,BARASSI C,et al.Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression[J].Blood,2006,107(12):4825-4833.
[9] TENORIO A R.The monoclonal CCR5 antibody PRO-140: the promise of once-weekly HIV therapy[J].Curr HIV/AIDS Rep,2011,8(1):1-3.
[10] LOPALCO L.Natural anti-CCR5 antibodies in HIV-infection and-exposure[J].J Transl Med,2011,9(Suppl 1 S4):1-11.
[11] PASTORI C,CLIVIO A,DIOMEDE L.Two amino acid substitutions within the first external loop of CCR5 induce human immunodeficiency virus-blocking antibodies in mice and chickens[J].J Virol,2008,82(8):4125-4134.
[12] HUNTER Z,SMYTH H D,DURFEE P,et al.Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine[J].Vaccine,2009,28(2):403-414.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录